ConductScience.org, home

Paper42101653

Novel recombinant protein PK5-Gal-3C enhances the anti-tumor activity of T cells via binding with TRPV2.

Zhang G and 9 others. Cancer Immunol Immunother, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Novel recombinant protein PK5-Gal-3C enhances the anti-tumor activity of T cells via binding with TRPV2. Papers, record 42101653. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42101653

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Novel recombinant protein PK5-Gal-3C enhances the anti-tumor activity of T cells via binding with TRPV2.
PubMed
Journal
Cancer Immunol Immunother
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-09-22
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhang GGuopeng
2Zhang WWei
3Wei XXiaohuan
4Wang ZZhenyu
5Wang FFeitong
6Sun SShishuo
7Xu HHaiheng
8Liu XXiangye
9Zhang QQing
10Gao XXiaoge

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
TRPV Cation ChannelsMajor topic
T-LymphocytesMajor topic
Galectin 3Major topic
Immunotherapy, AdoptiveMajor topic
Calcium ChannelsMajor topic
Animals
Humans
Mice
Recombinant Proteins
Cell Line, Tumor
Lymphocyte Activation

Source PubMed

Download CSV of topics

Grants8

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
XWKYHT20240123Science and Technology Project of Xuzhou Municipal Health CommissionPubMed
82473333National Natural Science Foundation of ChinaPubMed
81972242National Natural Science Foundation of ChinaPubMed
BE2023689Jiangsu Province Social Development ProjectsPubMed
QL-YB032XZHMU-QL Joint Research FundPubMed
LCZX202501Construction Project of High Level Hospital of Jiangsu ProvincePubMed
BK20150216Natural Science Foundation of Jiangsu ProvincePubMed
20KJA320006Natural Science Key Project of Jiangsu Provincial Education DepartmentPubMed

Source PubMed

Download CSV of grants

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum in42616099Correction: Novel recombinant protein PK5-Gal-3C enhances the anti-tumor activity of T cells via binding with TRPV2.https://conductscience.org/library/papers/42616099

Source PubMed

Download CSV of comments and corrections

References39

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132735779Engineering CAR-T Cells for Next-Generation Cancer Therapy.Cancer Cell2020https://conductscience.org/library/papers/32735779PubMed
238295165N-glycosylation as a eukaryotic protective mechanism against protein aggregation.Sci Adv2024https://conductscience.org/library/papers/38295165PubMed
321574765Mast-cell degranulation induced by physical stimuli involves the activation of transient-receptor-potential channel TRPV2.Physiol Res2012https://conductscience.org/library/papers/21574765PubMed
412796408Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer.Clin Cancer Res2003https://conductscience.org/library/papers/12796408PubMed
538353705Ion channel TRPV2 is critical in enhancing B cell activation and function.J Exp Med2024https://conductscience.org/library/papers/38353705PubMed
637548063Coengineering specificity, safety, and function into T cells for cancer immunotherapy.Immunol Rev2023https://conductscience.org/library/papers/37548063PubMed
723615321What do we know about the transient receptor potential vanilloid 2 (TRPV2) ion channel?FEBS J2013https://conductscience.org/library/papers/23615321PubMed
835624021Turning cold tumors hot: from molecular mechanisms to clinical applications.Trends Immunol2022https://conductscience.org/library/papers/35624021PubMed
938816425TCAF1 promotes TRPV2-mediated Ca2+ release in response to cytosolic DNA to protect stressed replication forks.Nat Commun2024https://conductscience.org/library/papers/38816425PubMed
1029072683Plasminogen kringle 5 suppresses gastric cancer via regulating HIF-1α and GRP78.Cell Death Dis2017https://conductscience.org/library/papers/29072683PubMed
1132612154The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications.Cell Mol Immunol2020https://conductscience.org/library/papers/32612154PubMed
1238382538Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance.Annu Rev Immunol2024https://conductscience.org/library/papers/38382538PubMed
1322419253The immune contexture in human tumours: impact on clinical outcome.Nat Rev Cancer2012https://conductscience.org/library/papers/22419253PubMed
1414991772RGA protein associates with a TRPV ion channel during biosynthesis and trafficking.J Cell Biochem2004https://conductscience.org/library/papers/14991772PubMed
1523420671The role of transient receptor potential vanilloid type-2 ion channels in innate and adaptive immune responses.Front Immunol2013https://conductscience.org/library/papers/23420671PubMed
1635638332Disulfiram bolsters T-cell anti-tumor immunity through direct activation of LCK-mediated TCR signaling.EMBO J2022https://conductscience.org/library/papers/35638332PubMed
1723470321Molecular mechanisms of T cell co-stimulation and co-inhibition.Nat Rev Immunol2013https://conductscience.org/library/papers/23470321PubMed
1836689620Herpes Virus Entry Mediator Costimulation Signaling Enhances CAR T-cell Efficacy Against Solid Tumors Through Metabolic Reprogramming.Cancer Immunol Res2023https://conductscience.org/library/papers/36689620PubMed
1925903376Functional expression of TRPV channels in T cells and their implications in immune regulation.FEBS J2015https://conductscience.org/library/papers/25903376PubMed
2034873817Towards understanding the extensive diversity of protein N-glycan structures in eukaryotes.Biol Rev Camb Philos Soc2022https://conductscience.org/library/papers/34873817PubMed

See all 39 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42101653

GET https://conductscience.org/api/papers/v1/42101653/references?page=2